Genmab | GEN - Selling And Administration Expenses


Genmab reported DKK208M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.94B 237M Dec/2025
argenx SE USD 429.62M 93.32M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bayer EUR 4.05B 647M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Demant DKK 6.09B 135M Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Fresenius Medical Care EUR 785M 79.56M Dec/2025
Galapagos EUR 44.42M 9.87M Dec/2025
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GN Store Nord DKK 1.45B 41M Dec/2025
GRIFOLS EUR 275.3M 9.7M Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Merck EUR 1.6B 136M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.47B 193M Dec/2025